meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
2
mUC - L2 - PDL1 positive
3
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
Hemoglobin concentration < 10g/dl
hemoglobin concentration > 10g/dl
metastasis (liver )
metastasis (lymph node )
metastasis (visceral)
PD-L1 < 1%
PD-L1 < 10%
PD-L1 > 1%
PD-L1 > 10%
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
DOR (extension)
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Blood and lymphatic system disorders AE (grade 3-4)
Blood creatinine increased AE (grade 3-4)
Cardiac disorders AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dry skin AE (grade 3-4)
Dysgeusia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Endocrine disorders AE (grade 3-4)
Eye disorders AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Gastrointestinal disorders AE (grade 3-4)
General disorders and administration site conditions AE (grade 3-4)
Headache AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Infections and infestations AE (grade 3-4)
Injury, poisoning and procedure AE (grade 3-4)
Investigations AE (grade 3-4)
Metabolism and nutrition disorders AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Musculoskeletal and connective tissue disorders AE (grade 3-4)
Myalgia AE (grade 3-4)
Nausea AE (grade 3-4)
Nervous system disorders AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Renal and urinary disorders AE (grade 3-4)
Respiratory, thoracic and mediastinal disorders AE (grade 3-4)
Skin and subcutaneous tissue disorders AE (grade 3-4)
Stomatitis AE (grade 3-4)
Vascular disorders AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
deaths (OS)
mUC - L2 - all population
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC)
1
certainty unassessable
-14%
pembrolizumab alone vs. Standard of Care (SoC)
1
certainty unassessable
statistically conclusive
-25%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open